RU1811846C - Method of erysipelatous inflammation treatment - Google Patents

Abstract

The invention relates to the field of medicine and relates to the pharmacotherapy of infectious diseases, namely, methods for treating erysipelas. Patients are prescribed antibacterial therapy, antihistamines. Additionally, later lincomycin is prescribed at 0.6 g 3 times a day for 7-10 days, zymosan at 1.0 ml 1 time per day intramuscularly for 7-10 days and locally at the lesion site - trypsin electrophoresis, crystalline during 10 days. At the same time, the treatment efficiency increases, in particular, the number of subsequent relapses of erysipelas decreases, the number of allergic reactions and toxic lesions of the hepatobiliary system decreases), which makes it advisable to use the proposed method of treatment in conditions of infectious hospitals of any level. 1 tab. ate with

Description

The invention relates to medicine and relates to methods for treating infectious diseases.

The aim of the invention is to increase the effectiveness of the existing method of treating erysipelas and reduce the number of adverse reactions.

To this end, in addition to being. In the current method, a domestic preparation of zymosan is prescribed, 1.0 ml once a day intramuscularly for 7-10 days, and the place on the lesion site is crystalline trypsin electrophoresis for 10 days.

The use of this method is based on the property of zymosan, first discovered by the authors, to significantly reduce the incidence of side effects of lincomycin in patients with erysipelas, in particular, allergic reactions and liver damage. Based on the materials obtained by the authors of the applications, it was found that trypsin

when administered in the form of electrophoresis to the site of erysipelas, it helps to normalize the local immunity of the skin and eliminate the condition of the ancestral dermis in the focus, as a result of which microcirculation is normalized and the frequency of subsequent recurrence is reduced. At the same time, zymosan prevents the development of allergic reactions to trypsin, as a result of which, in a single complex, these two drugs complement each other's effect.

The method is carried out as follows: the patient is treated with antibiotics, antihistamines and. vitamins, after completion of the course of treatment, the level of SK antigen is determined, and when it is increased, lincomycin, zymosan and crystalline trypsin electrophoresis are prescribed in place of erysipelas.

oo

00

4

about

Lincomycin is administered intramuscularly at a dose of 0.6 g three times a day for 7-10 days, zymosan - intramuscularly at 1 ml 1 time per day for the same time, trypsin in the form of electrophoresis, for which 10 mg of trypsin is dissolved in 15-20 ml of distilled water is administered from the negative pole. The possibility of using trypsin in the form of electrophoresis is provided for by the drug instruction approved by the USSR Ministry of Health.

The proposed method for the treatment of erysipelas is tested by the authors of the proposal in 102 patients with a recurring form of erysipelas. For comparison, 104 patients with a recurring form of erysipelas, treated according to the existing prototype method, were also examined. Clinical indicators were analyzed - the frequency of allergic reactions to the administration of lincomycin, toxic complications from the liver, as well as indicators of general and local immunity after completing the full course of treatment of the patient (before discharge from the hospital), liver function tests and the frequency of subsequent relapse of erysipelas during the one-year follow-up period after discharge. The clinical course of erysipelas, sex and age characteristics, and occupations of the onal groups of patients in both groups were the same. The data obtained are presented in table form.

As follows from the table, the treatment of patients with erysipelas with the proposed method reduces the frequency of allergic reactions to lincomycin administration by 3.7 times, toxic lesions of the hepatobiliary system by 3.7 times, and the number of relapses during a one-year follow-up period by 3.2 times. There was also documented a higher number of T-lymphocytes (by 15 ± 2% compared with the prototype) and active T-lymphocytes (by 16 ± 2%), skin bactericidal index in the local focus (by 24 ± 2%) in patients receiving additional zymosan and trypsin. By the time of discharge from the hospital, the ALAT level of patients treated by the proposed method was normal and on average 2.8 times lower than that of patients treated according to the existing method. This indicates an improvement in the functional activity of the liver under the influence of treatment with zymosan and trypsin.

Example. Patient K., 50 years old, senior master, was admitted to the infectious diseases department on March 16, 86 with complaints of weakness, headache, fever, pain in the right leg, redness and swelling. 8 patient history since 1980 erysipelas of the right tibia, suffered 15 relapses, which were initially 1-2 times a year, last year - 4 relapses. On examination: hyperemia and edema of the right lower leg, lesion site with clear boundaries and uneven edges, painful on palpation. Set

the diagnosis of often recurring erysipelas of the right lower leg, erythematous form, moderate, Penicillin was treated with a daily dose of 3 million units, ascorutin, diphenhydramine. The patient's condition returned to normal, hyperemia and edema disappeared. In the study of 29.03. a 2.2-fold increase in the level of SK antigen was noted in comparison with the norm. In this regard, a course of treatment with lincomycin 0.6 g 3 times

per day intramuscularly for 7 days, zymosan 1.0 g per day for 10 days, trypsin electrophoresis to the site of erysipid focus No. 10. Discharged in satisfactory condition after completion of the course of treatment.

When prescribing T cells - 52%, active ROCK

- 46%. skin bactericidal ™ index - 85%, serum ALAT activity - 0.84

μmol / l.sec. Allergic and toxic

reactions to drug administration were not noted. Discharged on April 9, 86. Clinical observation for 2.5 years after discharge allowed us to ascertain the absence of relapse. Repeated study of general and local immunity after 6 months, 1 year and 2

years after discharge showed that his indicators are close to normal.

Thus, the proposed method for the treatment of erysipelas has advantages over the existing one, which consists in increasing the effectiveness of the treatment, in particular, reducing the number of subsequent relapses of erysipelas, reducing the number of allergic reactions and toxic lesions of the hepatobiliary system. In connection with the improvement of indicators of general and local immunity, the likelihood of occurrence of recurrence of erysipelas when using the proposed method is significantly reduced.

.. The method is not complicated to implement and can be used to treat patients with erysipelas as in an infectious diseases hospital, as well as, if necessary, in an outpatient setting.

Complications and side effects from the therapy were not noted, its tolerability by patients is good.

Claims (1)

SUMMARY OF THE INVENTION A method for treating erysipelas, comprising administering an antibiotic, anti- (islamic drugs, vitamins and lincomycin, characterized in that, with In order to reduce relapses and reduce similar effects of therapy, zymosan is additionally administered and trypsin electrophoresis is performed on the local area of inflammation.